title: Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.
abstract: As the incidence of calcific aortic valve stenosis increases with the aging of the population, improved understanding and novel therapies to reduce its progression and need for aortic valve replacement are urgently needed.
  
  
  
  Lipoprotein(a) is the only monogenetic risk factor for calcific aortic stenosis. Elevated levels are a strong, causal, independent risk factor, as demonstrated in epidemiological, genome-wide association studies and Mendelian randomization studies. Lipoprotein(a) is the major lipoprotein carrier of oxidized phospholipids, which are proinflammatory and promote calcification of vascular cells, two key pathophysiological drivers of aortic stenosis. Elevated plasma lipoprotein(a) and oxidized phospholipids predict progression of pre-existing aortic stenosis and need for aortic valve replacement. The failure of statin trials in pre-existing aortic stenosis may be partially due to an increase in lipoprotein(a) and oxidized phospholipid levels caused by statins. Antisense oligonucleotides targeted to apo(a) are in Phase 2 clinical development and shown to lower both lipoprotein(a) and oxidized phospholipids.
  
  
  
  Lipoprotein(a) and oxidized phospholipids are key therapeutic targets in calcific aortic stenosis. Strategies aimed at potent lipoprotein(a) lowering to normalize levels and/or to suppress the proinflammatory effects of oxidized phospholipids may prevent progression of this disease.
authors.affiliation: Division of Cardiovascular Diseases, Sulpizio Cardiovascular Center, Department of Medicine, University of California San Diego, La Jolla, California, USA.
authors.forename: Calvin
authors.initials: C
authors.lastname: Yeang
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Wilkinson
authors.forename: Sotirios
authors.initials: S
authors.lastname: Tsimikas
mesh_terms: D001021:Aortic Valve / Q000473:pathology*; D001024:Aortic Valve Stenosis / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D002114:Calcinosis; D055106:Genome-Wide Association Study; D006801:Humans; D017270:Lipoprotein(a) / Q000037:antagonists & inhibitors* / Q000097:blood / Q000235:genetics; D010743:Phospholipids / Q000494:pharmacology*
chemical_list: D017270:Lipoprotein(a); D010743:Phospholipids